Stockreport

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain [Yahoo! Finance]

OKYO Pharma Limited - Ordinary Shares  (OKYO) 
PDF bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-rela [Read more]